LLG 783

Drug Profile

LLG 783

Alternative Names: LLG783

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis Pharmaceuticals
  • Class Cardiovascular therapies; Monoclonal antibodies
  • Mechanism of Action LDL receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Intermittent claudication; Peripheral arterial disorders

Most Recent Events

  • 20 Sep 2017 Phase-II clinical trials in Intermittent claudication in USA (IV) (NCT03194776)
  • 20 Sep 2017 Phase-II clinical trials in Peripheral arterial disorders in USA (IV) (NCT03194776)
  • 19 Jun 2017 Novartis Pharmaceuticals plans a phase II trial for Peripheral arterial disorders (In adults, In the elderly, Treatment-experienced) and Intermittent claudication (In adults, In the elderly, Treatment-experienced) (IV) (NCT03194776)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top